Your browser doesn't support javascript.
loading
Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications.
Fermand, Jean-Paul; Bridoux, Frank; Dispenzieri, Angela; Jaccard, Arnaud; Kyle, Robert A; Leung, Nelson; Merlini, Giampaolo.
Afiliación
  • Fermand JP; Service d'Immuno-Hématologie, Département d'Immunologie Clinique, INSERM (Unité Mixte de Recherche 1126), and Intergroupe Francophone du Myélome, Hôpital Saint-Louis, Paris, France.
  • Bridoux F; Service de Néphrologie and Centre de référence pour l'amylose AL et autres maladies par dépôts d'immunoglobulines monoclonales, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
  • Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Jaccard A; Service d'Hématologie and Centre de référence pour l'amylose AL et autres maladies par dépôts d'immunoglobulines monoclonales, Centre Hospitalier Universitaire de Limoges, Limoges, France.
  • Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Leung N; Division of Nephrology, Mayo Clinic, Rochester, MN.
  • Merlini G; Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy; and.
Blood ; 132(14): 1478-1485, 2018 10 04.
Article en En | MEDLINE | ID: mdl-30012636
Monoclonal gammopathy is a common condition, particularly in the elderly. It can indicate symptomatic multiple myeloma or another overt malignant lymphoid disorder requiring immediate chemotherapy. More frequently, it results from a small and/or quiescent secreting B-cell clone, is completely asymptomatic, and requires regular monitoring only, defining a monoclonal gammopathy of unknown significance (MGUS). Sometimes, although quiescent and not requiring any treatment per se, the clone is associated with potentially severe organ damage due to the toxicity of the monoclonal immunoglobulin or to other mechanisms. The latter situation is increasingly observed but still poorly recognized and frequently undertreated, although it often requires rapid specific intervention to preserve involved organ function. To improve early recognition and management of these small B-cell clone-related disorders, we propose to introduce the concept of monoclonal gammopathy of clinical significance (MGCS). This report identifies the spectrum of MGCSs that are classified according to mechanisms of tissue injury. It highlights the diversity of these disorders for which diagnosis and treatment are often challenging in clinical practice and require a multidisciplinary approach. Principles of management, including main diagnostic and therapeutic procedures, are also described. Importantly, efficient control of the underlying B-cell clone usually results in organ improvement. Currently, it relies mainly on chemotherapy and other anti-B-cell/plasma cell agents, which should aim at rapidly producing the best hematological response.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Paraproteinemias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Blood Año: 2018 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Paraproteinemias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Blood Año: 2018 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos